133 related articles for article (PubMed ID: 29549809)
41. Fas/APO-1 (CD95) expression in myelodysplastic syndromes.
Lepelley P; Grardel N; Erny O; Iaru T; Obein V; Cosson A; Fenaux P
Leuk Lymphoma; 1998 Jul; 30(3-4):307-12. PubMed ID: 9713962
[TBL] [Abstract][Full Text] [Related]
42. Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.
Castelli R; Schiavon R; Rossi V; Deliliers GL
Med Oncol; 2018 Apr; 35(5):76. PubMed ID: 29675620
[TBL] [Abstract][Full Text] [Related]
43. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.
Kantarjian H; Fenaux P; Sekeres MA; Becker PS; Boruchov A; Bowen D; Hellstrom-Lindberg E; Larson RA; Lyons RM; Muus P; Shammo J; Siegel R; Hu K; Franklin J; Berger DP
J Clin Oncol; 2010 Jan; 28(3):437-44. PubMed ID: 20008626
[TBL] [Abstract][Full Text] [Related]
44. Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.
Buccisano F; Piccioni AL; Nobile C; Criscuolo M; Niscola P; Tatarelli C; Fianchi L; Villivà N; Neri B; Carmosino I; Gumenyuk S; Mancini S; Voso MT; Maurillo L; Breccia M; Zini G; Venditti A; Fenu S; Spiriti MA; Latagliata R;
Ann Hematol; 2016 Jun; 95(7):1059-65. PubMed ID: 27091349
[TBL] [Abstract][Full Text] [Related]
45. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
[TBL] [Abstract][Full Text] [Related]
46. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
47. Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome.
Rosenfeld C; Bedell C
Leuk Res; 2002 Aug; 26(8):721-4. PubMed ID: 12191566
[TBL] [Abstract][Full Text] [Related]
48. A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes.
Jang JH; Harada H; Shibayama H; Shimazaki R; Kim HJ; Sawada K; Mitani K
Int J Hematol; 2015 Oct; 102(4):401-12. PubMed ID: 26323997
[TBL] [Abstract][Full Text] [Related]
49. Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function.
Castelli R; Deliliers GL; Colombo R; Moreo G; Gallipoli P; Pantaleo G
Ann Hematol; 2014 Sep; 93(9):1523-9. PubMed ID: 24711171
[TBL] [Abstract][Full Text] [Related]
50. [Lower risk myelodysplastic syndrome patients with transfusion dependent treated by dose-reduced decitabine].
Fang BZ; Liu ZZ; He GS; Miao M; Wang XL; Qiu HY; Jin ZM; Tang XW; Han Y; Fu ZZ; Ma X; Sun AN; Wu DP; Ruan CG
Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(40):3189-92. PubMed ID: 24405538
[TBL] [Abstract][Full Text] [Related]
51. Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials.
Prica A; Sholzberg M; Buckstein R
Br J Haematol; 2014 Dec; 167(5):626-38. PubMed ID: 25155450
[TBL] [Abstract][Full Text] [Related]
52. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Maurillo L; Breccia M; Buccisano F; Voso MT; Niscola P; Trapè G; Tatarelli C; D'Addosio A; Latagliata R; Fenu S; Piccioni AL; Fragasso A; Aloe Spiriti MA; Refrigeri M; Criscuolo M; Musto P; Venditti A
Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
[TBL] [Abstract][Full Text] [Related]
53. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.
Santini V; Almeida A; Giagounidis A; Gröpper S; Jonasova A; Vey N; Mufti GJ; Buckstein R; Mittelman M; Platzbecker U; Shpilberg O; Ram R; Del Cañizo C; Gattermann N; Ozawa K; Risueño A; MacBeth KJ; Zhong J; Séguy F; Hoenekopp A; Beach CL; Fenaux P
J Clin Oncol; 2016 Sep; 34(25):2988-96. PubMed ID: 27354480
[TBL] [Abstract][Full Text] [Related]
54. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies.
Selleri C; Maciejewski JP; Catalano L; Ricci P; Andretta C; Luciano L; Rotoli B
Cancer; 2002 Nov; 95(9):1911-22. PubMed ID: 12404285
[TBL] [Abstract][Full Text] [Related]
55. Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies.
Krendyukov A; Gieffers C
Cancer Manag Res; 2019; 11():8095-8100. PubMed ID: 31564969
[TBL] [Abstract][Full Text] [Related]
56. Hematopoietic growth factors in myelodysplastic syndromes.
Steensma DP
Semin Oncol; 2011 Oct; 38(5):635-47. PubMed ID: 21943670
[TBL] [Abstract][Full Text] [Related]
57. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
List AF; Baker AF; Green S; Bellamy W
Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
[TBL] [Abstract][Full Text] [Related]
58. Erythropoiesis stimulating agents and other growth factors in low-risk MDS.
Hellström-Lindberg E; van de Loosdrecht A
Best Pract Res Clin Haematol; 2013 Dec; 26(4):401-10. PubMed ID: 24507816
[TBL] [Abstract][Full Text] [Related]
59. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
60. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes.
Stasi R; Brunetti M; Bussa S; Conforti M; Di Giulio C; Crescenzi A; Terzoli E; Vecchione A; Pagano A
Clin Cancer Res; 1997 May; 3(5):733-9. PubMed ID: 9815743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
